Showing 8451-8460 of 8647 results for "".
- Group of Takeda Shareholders Call Proposed Shire Purchase “Height of Madness”https://modernod.com/news/group-of-takeda-shareholders-call-proposed-shire-purchase-height-of-madness/2480115/A group of Takeda shareholders have criticized the company’s deal to buy Shire as “the height of madness,” raising concerns over the level of debt that will need to be taken on to fund the purchase, the Financial Times reported. The group hold just over 1 percent of Takeda’
- Orasis Pharmaceuticals Closes $13 Million Series B Financinghttps://modernod.com/news/orasis-pharmaceuticals-closes-13-million-series-b-financing/2480119/Privately-held Orasis Pharmaceuticals announced the closing of a $13 million Series B financing to be used to advance Orasis’s lead product candidate, CSF-1, an eye drop being developed for the treatment of presbyopia symptoms, through completion of its phase 2b clinical trial. The proceeds will
- FDA Commissioner Scott Gottlieb Proposes Modernization of FDA’s Drug Review Officehttps://modernod.com/news/fda-commissioner-scott-gottlieb-provides-statement-on-proposed-modernization-of-fdas-drug-review-office/2480120/FDA Commissioner Scott Gottlieb, MD, released a statement Monday outlining the agency’s position on a proposed modernization of FDA’s Drug Review Office. The statement reads: “Scientific and medical advances are giving the FDA more opportunities to more fully address diseases a
- Bausch + Lomb Enrolls First Patient in Envista MX60EF Trifocal IOL Clinical Trialhttps://modernod.com/news/bausch-lomb-enrolls-first-patient-in-envista-mx60ef-trifocal-iol-clinical-trial/2480122/Bausch + Lomb announced that it has enrolled the first patient in a clinical trial studying the efficacy and safety of an investigational trifocal IOL, the enVista MX60EF. The study is intended to support a premarket approval (PMA) application filing with the FDA. The enVista MX60EF trifoc
- Trump Says Drug Companies to Unveil Price Cuts in Two Weekshttps://modernod.com/news/trump-says-drug-companies-to-unveil-price-cuts-in-two-weeks/2480129/Major pharmaceutical companies will announce “voluntary, massive” cuts in drug prices in two weeks, President Donald Trump said Wednesday, without providing details, according to a
- White Light Exposure Suppresses Melatonin Secretion in Many Blind Peoplehttps://modernod.com/news/white-light-exposure-suppresses-melatonin-secretion-in-many-blind-people/2480138/Ocular exposure to white light suppresses melatonin secretion in nearly a third of totally blind individuals, researchers report, according to Medscape. Ocular exposure to light inhibits pineal melatonin secretion in humans by way o
- New Type of Treatable Vertigo Identifiedhttps://modernod.com/news/new-type-of-treatable-vertigo-identified/2480140/Investigators have identified a new type of vertigo that may be treatable, according to a report in Medscape. This recurrent spontaneous vertigo (RSV) is not accompanied by neurologic symptoms and doesn’t satisfy the diagnosis
- Gene Therapies That Could Transform Diseases Get Easier FDA Pathhttps://modernod.com/news/gene-therapies-that-could-transform-diseases-get-easier-fda-path/2480144/New therapies that may cure diseases caused by defective genes will get a faster path to approval by U.S. regulators, part of an effort by the FDA to keep pace with one of biotechnology’s fastest-growing fields, according to a Bloomberg
- Tear Film Innovations Completes $8.5 Million Series B Fundinghttps://modernod.com/news/tear-film-innovations-completes-8-5-million-series-b-funding/2480145/Tear Film Innovations announced it has completed a $8.5 million Series B Preferred Stock funding round led by Visionary Ventures Fund LP and Bluestem Capital. “This successful funding round completes the capitalization for our growth strategy. We are currently making key hires to meet the
- Ex-Valeant Executive Guilty of Taking Pharmacy CEO’s Bribehttps://modernod.com/news/ex-valeant-executive-guilty-of-taking-pharmacy-ceos-bribe/2480147/A former Valeant Pharmaceuticals executive was found guilty of accepting a $10 million bribe for manipulating the company’s takeover of a startup mail-order pharmacy in 2014, according to a